Patents Examined by Umamaheswari Ramachandran
  • Oxprenolol compositions for treating cancer
    Patent number: 10828270
    Abstract: The present invention relates to compositions of S-enantiomer enriched oxprenolol and their use in treating cancer and treating or preventing, in cancer patients, cachexia, body weight loss, lean body mass loss and adipose tissue loss, and improving quality of life and prolonging survival of cancer patients.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: November 10, 2020
    Assignee: Actimed Therapeutics Limited
    Inventors: Andrew J. S. Coats, Stefan Anker, Jochen Springer
  • Use of cranberry proanthocyanidin for treatment of oropharyngeal bacterial colonization
    Patent number: 10828342
    Abstract: The present invention relates to a method for preventing Gram-negative bacterial colonization of an oropharyngeal material, the said method comprising bringing into contact a composition comprising a cranberry-derived proanthocyanidin extract on at least a part of the surface area of the said material.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: November 10, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DIDEROT—PARIS 7, ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS
    Inventors: Jean-Damien Ricard, Dimitri Margetis
  • Pharmaceutical combination
    Patent number: 10813890
    Abstract: A pharmaceutical combination comprising as components (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and (b) at least one NMDA-antagonist, a pharmaceutical formulation and a dosage form comprising such a combination, and a method of treating pain, e.g. inflammatory pain or neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, with component (a) being administered either before or after component (b), and with components (a) or (b) being administered to the mammal either via the same pathway of administration or via different pathways of administration.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: October 27, 2020
    Assignee: Grünenthal GmbH
    Inventors: Klaus Schiene, Petra Bloms-Funke
  • Casein kinase 1 delta inhibitor
    Patent number: 10815230
    Abstract: The present invention provides 2-Methyl-amino-3-[(4-fluorophenyl)carbonyl]indolizine-1-carboxamide of formula (I) or a pharmaceutically acceptable salt thereof; and its therapeutic uses in the treatment of neurodegenerative disorders, in particular tauopathies and most preferably in the treatment of Alzheimer's disease.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: October 27, 2020
    Assignee: ELECTROPHORETICS LIMITED
    Inventors: Ian H. Pike, Karsten Kuhn, Stefan Kienle, William D. O. Hamilton, Jonathan R. Heal, Joseph M. Sheridan
  • Compositions for the treatment of hypertension
    Patent number: 10799487
    Abstract: Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: October 13, 2020
    Assignee: THE GEORGE INSTITUTE FOR GLOBAL HEALTH
    Inventors: Anthony Rodgers, Stephen MacMahon
  • Compositions and methods for treating ocular disorders
    Patent number: 10799481
    Abstract: The present disclosure is directed to compositions comprising oxymetazoline and methods of treating various eye disorders related to drooping eyelids, such as ptosis, in a subject comprising administering to the subject compositions comprising oxymetazoline.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: October 13, 2020
    Assignee: RVL PHARMACEUTICALS, INC.
    Inventors: Tina deVries, David Jacobs
  • Combination of an inhibitor of PARP with an inhibitor of GSK-3 or DOT1L
    Patent number: 10799501
    Abstract: Provided herein is a pharmaceutical combination comprising (a) a poly-(ADP-ribose)-polymerase (PARP) inhibitor and (b) a second agent comprising (i) an inhibitor of glycogen synthase kinase 3 (GSK-3) or (ii) an inhibitor of disrupter of telomeric silencing 1-like (DOT1L). Also provided is a method of treating a subject suffering from acute myeloid leukaemia, comprising administering to the subject a therapeutically effective amount of the pharmaceutical combination.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: October 13, 2020
    Assignee: King's College Hospital NHS Foundation Trust
    Inventor: Chi Wai Eric So
  • Chemical compounds
    Patent number: 10793559
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: October 6, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Niall Andrew Anderson, Nicholas Paul Barton, Sebastien Andre Campos, Edward Paul Cannons, Anthony William James Cooper, Kenneth David Down, Kevin James Doyle, Julie Nicole Hamblin, Graham George Adam Inglis, Armelle Le Gall, Vipulkumar Kantibhai Patel, Simon Peace, Andrew Sharpe, Gemma Victoria White
  • Tobacco products
    Patent number: 10780062
    Abstract: A tobacco product includes a dry powder composition comprising an amount of myo-inositol effective for treating and/or delaying onset of dysplastic lesions in the bronchial airway of an individual. A method for administering myo-inositol to an individual comprises the individual consuming the tobacco product.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: September 22, 2020
    Assignee: COLORADO CAN LLC
    Inventor: Robert E. Sievers
  • Methods of regulating cannabinoid receptor activity-related disorders and diseases
    Patent number: 10772849
    Abstract: This disclosure concerns the discovery of the use of fenoterol analogues for regulating cannabinoid (CB) receptor activity-related disorders and disease, such as dysregulated CB receptors, including treating a disorder or disease, such as a glioblastoma, hepatocellular carcinoma, liver cancer, colon cancer, and/or lung cancer, which is associated with altered cannabinoid receptor activity. In one example, the method includes administering to a subject having or at risk of developing a disorder or disease regulated by CB receptor activity an effective amount of a fenoterol analogue to reduce one or more symptoms associated with the disorder or disease regulated by CB receptor activity.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: September 15, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Irving W. Wainer, Michel Bernier, Rajib K. Paul
  • High concentration medicant solutions for treating neurological disorders
    Patent number: 10772857
    Abstract: Highly concentrated solutions are disclosed along with methods of inhibiting and/or ameliorating functional neurological disorders of the brain. The method may include administering directly to a brain of a subject a medicament multiple times over a time period of at least two days. The medicament may include a half-life of less than 2 hour in the cerebrospinal fluid. The method may include inhibiting and/or ameliorating a functional neurological disorder of the brain using the medicant.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: September 15, 2020
    Assignee: Cerebral Therapeutics, Inc.
    Inventors: Daniel J. Abrams, Thomas Joseph Anchordoguy
  • Method of inhibiting tau phosphorylation
    Patent number: 10760052
    Abstract: A method of inhibiting phosphorylation of the tau protein and/or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system an effective amount of a of a compound or a pharmaceutically acceptable salt thereof that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1, and contains at least four of the six pharmacophores of FIGS. 35-40.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: September 1, 2020
    Assignee: Cassava Science, Inc.
    Inventors: Hoau-Yan Wang, Lindsay Burns Barbier
  • Treatment of allergic rhinitis using a combination of mometasone and olopatadine
    Patent number: 10758550
    Abstract: The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a pediatric human subject) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: September 1, 2020
    Assignee: GLENMARK SPECIALTY S.A.
    Inventors: Neelima Khairatkar-Joshi, Abhay Kulkarni, Pradeep D. Wale, Vikram M. Bhosale, Piyush Agarwal, Patrick Keohane, Sudeesh K. Tantry, Chad Oh
  • Use of inhibitors of Bruton's tyrosine kinase (Btk)
    Patent number: 10751342
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: August 25, 2020
    Assignee: Pharmacyclics LLC
    Inventors: Joseph J. Buggy, Gwen Fyfe, Lee Honigberg, David J. Loury
  • [2.2.2] bicyclic derivatives and methods of use
    Patent number: 10751307
    Abstract: Administration of a salt of bi-cyclo [2.2.2] octane-2-carbonic acid reduces dysphoria in dysphoric subjects, ameliorates ethanol craving in alcoholics, reduces the erythrocyte sedimentation rate and the level of liver function markers (AST, ALT, and bilirubin) in human subjects, and reduces the number or strength of seizures in epileptics.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: August 25, 2020
    Inventor: Susanna A. Saakian
  • Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer
    Patent number: 10751332
    Abstract: The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and R1 to R8 are defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: August 25, 2020
    Assignee: Asana BioSciences, LLC
    Inventors: Aranapakam M. Venkatesan, Scott K. Thompson, Roger A. Smith, Sanjeeva P. Reddy, Raghava Reddy Kethiri, Purushottam M. Dewang, Gurulingappa Hallur, Chandrika Mulakala
  • Treatment of conditions through pharmacological modulation of the autonomic nervous system
    Patent number: 10702533
    Abstract: Methods are provided for treating a subject for a condition caused by an abnormality in the subject's autonomic nervous system. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is pharmacologically modulated with at least one beta-blocker in a manner that is effective to treat the subject for the condition. The subject methods find use in the treatment of a variety of different conditions, where such conditions include various disease conditions. Also provided are systems and kits for use in practicing the subject methods.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: July 7, 2020
    Assignee: Palo Alto Investors
    Inventors: Anthony Joonkyoo Yun, Patrick Yuarn-Bor Lee
  • Compounds and compositions for treating chemical warfare agent-induced injuries
    Patent number: 10703754
    Abstract: Compounds and compositions for treating injuries caused by exposure to chemical warfare agents are described herein.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: July 7, 2020
    Assignee: Eli Lilly and Company
    Inventor: Jayhong A. Chong
  • Treatment of debilitating fatigue
    Patent number: 10702512
    Abstract: The present disclosure relates to a dopamine stabilizing agent and an anti-depressive agent for use in the treatment of disorders characterized by debilitating fatigue, such as myalgic encephalomyelitis (ME)/Chronic fatigue syndrome (CFS), fibromyalgia (FM) and depression, as well as of combinations thereof. Related treatment methods, pharmaceutical compositions and combination kits are also disclosed.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: July 7, 2020
    Assignee: A. CARLSSON RESEARCH AB
    Inventors: Arvid Carlsson, Carl-Gerhard Gottfries
  • Bicyclic inhibitors of histone deacetylase
    Patent number: 10696673
    Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2).
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: June 30, 2020
    Assignee: Rodin Therapeutics, Inc.
    Inventors: Nathan Oliver Fuller, John A. Lowe, III